In-situ tumor vaccination: Bringing the fight to the tumor

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 8, 2015, Pages 1901-1909

  Pierce, Robert H ^a   Campbell, Jean S ^a   Pai, Sara I ^b   Brody, Joshua D ^c   Kohrt, Holbrook E K ^d  

^a Oncosec Medical Inc   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

Adaptive resistance; Immunotherapy; Intratumoral; Melanoma

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2, 3 DIOXYGENASE; INDUCIBLE T CELL COSTIMULATOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN S 100; RETINOIC ACID INDUCIBLE PROTEIN I; T LYMPHOCYTE RECEPTOR; T6 ANTIGEN; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER INFILTRATION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INFILTRATION; CELLULAR IMMUNITY; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IN SITU VACCINATION; INNATE IMMUNITY; LOW ENERGY RADIATION; MELANOMA; METASTASIS; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SOMATIC MUTATION; T LYMPHOCYTE; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS;

EID: 84944450609     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1049779     Document Type: Article

References (90)

1. Hobohm U. Fever therapy revisited. Brit J Cancer 2005; 92:421-5; PMID:15700041
2. Crittenden MR, Thanarajasingam U, Vile RG, Gough MJ. Intratumoral immunotherapy: using the tumour against itself. Immunology 2005; 114:11-22; PMID:15606790; http://dx. doi. org/10. 1111/j. 1365- 2567. 2004. 02001. x
3. Marabelle A, Kohrt H, Caux C, Levy R. Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res: Off J Am Assoc Cancer Res 2014; 20:1747-56; PMID:24691639; http://dx. doi. org/ 10. 1158/1078-0432. CCR-13-2116
4. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004; 58:862- 70.
5. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S. Fractionated but not single-dose radiotherapy induces an immunemediated abscopal effect when combined with anti- CTLA-4 antibody. Clin Cancer Res: Off J Am Assoc Cancer Res 2009; 15:5379-88; PMID:19706802; http://dx. doi. org/10. 1158/1078-0432. CCR-09-0265
6. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009; 114:589-95; PMID:19349616; http://dx. doi. org/10. 1182/blood-2009-02-206870
7. Sin JI, Park JB, Lee IH, Park D, Choi YS, Choe J, Celis E. Intratumoral electroporation of IL-12 cDNA eradicates established melanomas by Trp2(180-188)-specific CD8+ CTLs in a perforin/granzyme-mediated and IFN-gamma-dependent manner: application of Trp2 (180-188) peptides. Cancer Immunol, Immunother: CII 2012; 61:1671-82; PMID:22382361; http://dx. doi. org/10. 1007/s00262-012-1214-8
8. Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol, Biol, Phys 2005; 63:655-66; PMID:16199306; http://dx. doi. org/ 10. 1016/j. ijrobp. 2005. 06. 032
9. Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, Holt RA. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 2014; 24:743-50; PMID:24782321; http://dx. doi. org/10. 1101/gr. 165985. 113
10. Medzhitov R1, Janeway CA Jr. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol. 1997 Feb;9(1):4-9.
11. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348:124-8; PMID:25765070; http://dx. doi. org/10. 1126/science. aaa1348
12. van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, van Dijk LJ, Behjati S, Hilkmann H, El Atmioui D, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 2013; 31:e439-42; PMID:24043743; http://dx. doi. org/ 10. 1200/JCO. 2012. 47. 7521
13. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 2010; 28:4324-32; PMID:20697067; http://dx. doi. org/10. 1200/ JCO. 2010. 28. 9793
14. Salazar AM, Erlich RB, Mark A, Bhardwaj N, Herberman RB. Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial. Cancer Immunol Res 2014; 2:720-4; PMID:24801836; http://dx. doi. org/ 10. 1158/2326-6066. CIR-14-0024
15. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26:5896-903; PMID:19029422; http://dx. doi. org/10. 1200/JCO. 2007. 13. 9048
16. Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Investigat 2013; 123:2447-63; PMID:23728179; http://dx. doi. org/10. 1172/JCI64859
17. Tsung K, Norton JA. Lessons from Coley's Toxin. Surg Oncol 2006; 15:25-8; PMID:16814541; http://dx. doi. org/10. 1016/j. suronc. 2006. 05. 002
18. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994; 64:529-64; PMID:7724661; http://dx. doi. org/10. 1016/0163-7258(94)90023-X
19. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480:480-9; PMID:22193102; http://dx. doi. org/10. 1038/nature 10673
20. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6:715-27; PMID:16977338; http://dx. doi. org/10. 1038/nri1936
21. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84:4008-27; PMID:7994020
22. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Ann Rev Immunol 1995; 13:251-76; PMID:7612223; http://dx. doi. org/10. 1146/annurev. iy. 13. 040195. 001343
23. Germann T, Gately MK, Schoenhaut DS, Lohoff M, Mattner F, Fischer S, Jin SC, Schmitt E, Rude E. Interleukin- 12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells. Eur J Immunol 1993; 23:1762-70; PMID:8102100; http://dx. doi. org/10. 1002/eji. 1830230805
24. Huppa JB, Davis MM. T-cell-antigen recognition and the immunological synapse. Nat Rev Immunol 2003; 3:973-83; PMID:14647479; http://dx. doi. org/ 10. 1038/nri1245
25. Barry M, Bleackley RC. Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol 2002; 2:401-9; PMID:12093006
26. Groscurth P, Filgueira L. Killing mechanisms of cytotoxic T lymphocytes. News Physiol Sci: Int J Physiol Produced Jointly Int Union Physiol Sci Am Physiol Soc 1998; 13:17-21; PMID:11390753
27. Janeway CA, Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harbor Symposia Quant Biol 1989; 54 Pt 1:1-13; PMID:2700931; http://dx. doi. org/10. 1101/SQB. 1989. 054. 01. 003
28. Medzhitov R, Janeway CA Jr. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 1997; 9:4-9; PMID:9039775; http://dx. doi. org/ 10. 1016/S0952-7915(97)80152-5
29. Yu Z, Theoret MR, Touloukian CE, Surman DR, Garman SC, Feigenbaum L, Baxter TK, Baker BM, Restifo NP. Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J Clin Invest 2004; 114:551-9; PMID:15314692; http://dx. doi. org/10. 1172/ JCI200421695
30. Grohmann U, Belladonna ML, Vacca C, Bianchi R, Fallarino F, Orabona C, Fioretti MC, Puccetti P. Positive regulatory role of IL-12 in macrophages and modulation by IFN-gamma. J Immunol 2001; 167:221-7; PMID:11418652; http://dx. doi. org/10. 4049/ jimmunol. 167. 1. 221
31. Macatonia SE, Hsieh CS, Murphy KM, O'Garra A. Dendritic cells and macrophages are required for Th1 development of CD4+ T cells from alpha beta TCR transgenic mice: IL-12 substitution for macrophages to stimulate IFN-gamma production is IFN-gammadependent. Int Immunol 1993; 5:1119-28; PMID:7902129; http://dx. doi. org/10. 1093/intimm/ 5. 9. 1119
32. Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA 3rd, Kahler DJ, Pihkala J, Soler AP, Munn DH, et al. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2, 3 dioxygenase. Proc Natl Acad Sci U S A 2008; 105:17073-8; PMID:18952840; http://dx. doi. org/10. 1073/pnas. 0806173105
33. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252- 64; PMID:22437870; http://dx. doi. org/10. 1038/ nrc3239
34. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Translational Med 2013; 5:200ra116; PMID:23986400; http://dx. doi. org/10. 1126/scitranslmed. 3006504
35. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-30; PMID:24590637; http://dx. doi. org/10. 1200/JCO. 2013. 53. 0105
36. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515:568-71; PMID:25428505; http://dx. doi. org/10. 1038/nature13954
37. Choueiri TK, Fishman MN, Escudier BJ. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. J Clin Oncol 2014; 32:5s; Suppl; abstr 5012
38. Garon EB, Leighl NB, Rixvi NA, Blumenchein GR. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol 2014; 32:5s; (suppl; abstr 8020) 2014
39. Gettinger SN, Shepherd FA, Antonia SJ, Brahmer JR, Chow LQ, Juergens RA, Borghaei H, Shen Y, Harbison C, Alaparthy S, et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. J Clin Oncol 2014; 32:5s; 2014; Suppl; abstr 8024
40. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Dolled-Filhart M, Emancipator K, Gonzalez EJ, et al. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. San Antonio Breast Cancer Symp 2014; Abstract.
41. Creelan BC. Update on immune checkpoint inhibitors in lung cancer. Cancer Control: J Moffitt Cancer Center 2014; 21:80-9; PMID:24357746
42. Swanson MS, Sinha UK. Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer-review of current data. Oral Oncol 2015; 51:12-5; PMID:25459157; http://dx. doi. org/10. 1016/j. oraloncology. 2014. 10. 010
43. Zaravinos A. An updated overview of HPV-associated head and neck carcinomas. Oncotarget 2014; 5:3956- 69; PMID:24970795
44. Nanda R, Plimack ER, Dees EC, Shilpa G, Raanan B, Aymen E, Lajos P, Laurence B, Ravit G, Sara IP, et al. A phase Ib multicohort study of MK-3475 in patients with advanced solid tumors. J Clin Oncol 2014; 32:5s
45. Gubin MM1, Zhang X2, Schuster H3, Caron E4, Ward JP5, Noguchi T1, Ivanova Y1, Hundal J6, Arthur CD1, Krebber WJ7, Mulder GE7, Toebes M8, Vesely MD1, Lam SS1, Korman AJ9, Allison JP10, Freeman GJ11, Sharpe AH12, Pearce EL1, Schumacher TN8, Aebersold R13, Rammensee HG3, Melief CJ14, Mardis ER15, Gillanders WE2, Artyomov MN1, Schreiber RD1. Nature. 2014 Nov 27;515 (7528):577-81
46. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515:558-62; PMID:25428503; http://dx. doi. org/10. 1038/nature13904
47. Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, Bruno TC, Richmon JD, Wang H, Bishop JA, et al. Evidence for a role of the PD-1:PDL1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013; 73:1733-41; PMID:23288508; http://dx. doi. org/10. 1158/0008-5472. CAN-12-2384
48. Agrawal S, Reemtsma K, Bagiella E, Oluwole SF, Braunstein NS. Role of TAP-1 and/or TAP-2 antigen presentation defects in tumorigenicity of mouse melanoma. Cell Immunol 2004; 228:130-7; PMID:15219464; http://dx. doi. org/10. 1016/j. cellimm. 2004. 04. 006
49. Bald T, Landsberg J, Lopez-Ramos D, Renn M, Glodde N, Jansen P, Gaffal E, Steitz J, Tolba R, Kalinke U, et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Disc 2014; 4:674-87; PMID:24589924; http://dx. doi. org/10. 1158/2159-8290. CD-13-0458
50. Lim JY, Gerber SA, Murphy SP, Lord EM. Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol, Immunother: CII 2014; 63:259-71; PMID:24357146; http://dx. doi. org/10. 1007/s00262- 013-1506-7
51. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen- specific effector cells that traffic to the tumor. J Immunol 2005; 174:7516-23; PMID:15944250; http://dx. doi. org/10. 4049/jimmunol. 174. 12. 7516
52. Shiraishi K, Ishiwata Y, Nakagawa K, Yokochi S, Taruki C, Akuta T, Ohtomo K, Matsushima K, Tamatani T, Kanegasaki S. Enhancement of antitumor radiation efficacy and consistent induction of the abscopal effect in mice by ECI301, an active variant of macrophage inflammatory protein-1alpha. Clin Cancer Res: Off J Am Assoc Cancer Res 2008; 14:1159-66; PMID:18281550; http://dx. doi. org/10. 1158/1078- 0432. CCR-07-4485
53. Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2008; 15:3-12; PMID:18007663; http://dx. doi. org/10. 1038/sj. cdd. 4402269
54. Ullrich E, Bonmort M, Mignot G, Kroemer G, Zitvogel L. Tumor stress, cell death and the ensuing immune response. Cell Death Differ 2008; 15:21-8; PMID:17992190; http://dx. doi. org/10. 1038/sj. cdd. 4402266
55. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61; PMID:17187072; http://dx. doi. org/ 10. 1038/nm1523
56. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira JP, Delaloge S, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007; 220:47-59; PMID:17979839; http://dx. doi. org/10. 1111/j. 1600- 065X. 2007. 00573. x
57. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050-9; PMID:17704786; http://dx. doi. org/10. 1038/nm1622
58. Reits EA, Hodge JW, Herberts CA, Groothuis TA, ChakrabortyM, Wansley EK, Camphausen K, Luiten RM, de RuAH, Neijssen J, et al. Radiationmodulates the peptide repertoire, enhancesMHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006; 203:1259-71; PMID:16636135; http://dx. doi. org/ 10. 1084/jem. 20052494
59. Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget 2014; 5:403-16; PMID:24480782
60. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 2008; 180:3132-9; PMID:18292536; http://dx. doi. org/ 10. 4049/jimmunol. 180. 5. 3132
61. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 2014; 41:843-52; PMID:25517616; http://dx. doi. org/ 10. 1016/j. immuni. 2014. 10. 019
62. Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, Cameron TO, Babb JS, Schneider RJ, Formenti SC, Dustin ML, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 2008; 181:3099-107; PMID:18713980; http:// dx. doi. org/10. 4049/jimmunol. 181. 5. 3099
63. Kim JY, Son YO, Park SW, Bae JH, Chung JS, Kim HH, Chung BS, Kim SH, Kang CD. Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp Mol Med 2006; 38:474-84; PMID:17079863; http://dx. doi. org/10. 1038/emm. 2006. 56
64. Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WZ, Morales A, Abdulla F, Xing L, Navi D, et al. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood 2012; 119:355-63; PMID:22045986; http://dx. doi. org/10. 1182/blood-2011-05-355222
65. Kohrt H, Chu J, Brody JD. Dose-escalated, intratumoral TLR9 agonist and low-dose radiation induce abscopal effects in follicular lymphoma. Blood 2014; 124:3092-100; Meeting Abstract 3092; https://ash. confex. com/ash/2014/webprogram/Paper69392. html; PMID:25193870.
66. Brody J. In situ vaccination as a therapy for low-grade lymphoma. Clin Adv Hematol Oncol: H&O 2015; 13:26-8.
67. Billerbeck E, Labitt RN, Vega K, Frias-Staheli N, Dorner M, Xiao JW, Rice CM, Ploss A. Insufficient interleukin-12 signalling favours differentiation of human CD4(+) and CD8(+) T cells into GATA-3(+) and GATA-3(+) T-bet(+) subsets in humanized mice. Immunology 2014; 143:202-18; PMID:24766459; http://dx. doi. org/10. 1111/imm. 12304
68. Koch MA, Thomas KR, Perdue NR, Smigiel KS, Srivastava S, Campbell DJ. T-bet(+) Treg cells undergo abortive Th1 cell differentiation due to impaired expression of IL-12 receptor beta2. Immunity 2012; 37:501-10; PMID:22960221; http://dx. doi. org/ 10. 1016/j. immuni. 2012. 05. 031
69. Prochazkova J, Pokorna K, Holan V. IL-12 inhibits the TGF-beta-dependent T cell developmental programs and skews the TGF-beta-induced differentiation into a Th1-like direction. Immunobiology 2012; 217:74-82; PMID:21903294; http://dx. doi. org/10. 1016/j. imbio. 2011. 07. 032
70. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res: Off J Am Assoc Cancer Rese 1997; 3:409-17; PMID:9815699
71. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997; 90:2541- 8; PMID:9326219
72. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178:1223-30; PMID:8104230; http://dx. doi. org/10. 1084/jem. 178. 4. 1223
73. Colombo MP, Trinchieri G. Interleukin-12 in antitumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13:155-68; PMID:11900991; http://dx. doi. org/10. 1016/S1359- 6101(01)00032-6
74. Heinzerling L, Burg G, Dummer R, Maier T, Oberholzer PA, Schultz J, Elzaouk L, Pavlovic J, Moelling K. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther 2005; 16:35-48; PMID:15703487; http://dx. doi. org/10. 1089/hum. 2005. 16. 35
75. Mahvi DM, Henry MB, Albertini MR, Weber S, Meredith K, Schalch H, Rakhmilevich A, Hank J, Sondel P. Intratumoral injection of IL-12 plasmid DNA- results of a phase I/IB clinical trial. Cancer Gene Ther 2007; 14:717-23; PMID:17557109; http://dx. doi. org/ 10. 1038/sj. cgt. 7701064
76. Mazzolini G, Prieto J, Melero I. Gene therapy of cancer with interleukin-12. Curr Pharm Design 2003; 9:1981- 91; PMID:12871184; http://dx. doi. org/10. 2174/ 1381612033454261
77. Rook AH, Kubin M, Cassin M, Vonderheid EC, Vowels BR, Wolfe JT, Wolf SF, Singh A, Trinchieri G, Lessin SR. IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. J Immunol 1995; 154:1491-8
78. Rook AH, Wood GS, Yoo EK, Elenitsas R, Kao DM, Sherman ML, Witmer WK, Rockwell KA, Shane RB, Lessin SR, et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999; 94:902-8; PMID:10419880
79. Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, Benito A, Larrache J, Pueyo J, Subtil JC, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004; 22:1389-97; PMID:15084613; http:// dx. doi. org/10. 1200/JCO. 2004. 04. 059
80. Daud A, Algazi, A., Ashworth, M. T., Fong, L., Lewis, J. Chan, S. E., Heller, R. Pierce, R. H., Diep, T., Bhatia, S. Systemic antitumor effect and clinical response in a phase 2 trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma. J Clin Oncol 2014; 32:5s; 2014 (suppl; abstr 9025)
81. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996; 183:2541-50; PMID:8676075; http://dx. doi. org/10. 1084/jem. 183. 6. 2541
82. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA. Pillars article: CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994. 1: 405-413. Journal of immunology 2011; 187:3466-74; PMID:21934098; http://dx. doi. org/10. 1016/1074- 7613(94)90071-X
83. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001; 1:220-8; PMID:11905831; http://dx. doi. org/ 10. 1038/35105024
84. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 2010; 363:711-23; PMID:20525992; http://dx. doi. org/ 10. 1056/NEJMoa1003466
85. Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx. doi. org/10. 1056/NEJMoa1104621
86. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 2010; 21:1712-7; PMID:20147741; http://dx. doi. org/ 10. 1093/annonc/mdq013
87. Zhang R, Huynh A, Whitcher G, Chang J, Maltzman JS, Turka LA. An obligate cell-intrinsic function for CD28 in Tregs. J Clin Investigat 2013; 123:580-93; PMID:23281398
88. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, et al. Fc-dependent depletion of tumorinfiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013; 210:1695-710; PMID:23897981; http://dx. doi. org/10. 1084/jem. 20130579
89. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte- associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000; 192:295-302; PMID:10899916; http://dx. doi. org/ 10. 1084/jem. 192. 2. 295
90. Read S, Greenwald R, Izcue A, Robinson N, Mandelbrot D, Francisco L, Sharpe AH, Powrie F. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol 2006; 177:4376-83; PMID:16982872; http://dx. doi. org/ 10. 4049/jimmunol. 177. 7. 4376